Obsidian Therapeutics, Inc. announced presentations reporting initial clinical data from the ongoing first-in-human study of OBX-115 and preclinical data from our cytoDRiVE® platform demonstrating regulatable cytoTIL15 signal transduction in cis and trans, as well as the ability of a single DRD to coregulate two cytokines, LIGHT and mbIL15, in tumor-infiltrating lymphocytes during the AACR Annual Meeting, which will be held April 5-10, 2024 in San Diego, CA.
March 5, 2024
· 3 min read
